The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients

EuroIntervention 2017;13:788-795 published online May 2017. DOI: 10.4244/EIJ-D-16-01024

1. Monash Heart, Monash Medical Centre, and Monash University, Clayton, Victoria, Australia; 2. Clinique Pasteur, Toulouse, France; 3. The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; 4. Clinique Pasteur, Toulouse, France; 5. The Prince Char

Aims: The REPRISE IIE trial aimed to evaluate outcomes following transcatheter aortic valve implantation of the fully repositionable and retrievable LOTUS valve with a unique seal designe

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort